

Form PTO-1449

Attorney's Docket No.

39754-0672A

Application Serial No.

09/847,208

INFORMATION DISCLOSURE STATEMENT

Applicant(s) ANDREW SAXON et al.

Filing Date:

May 1, 2001

Group Art Unit:

1644

(Use several sheets if necessary)

18.

Elias et al., Post translational Addition of an Argine Moiety to Acidic NH₂ Termini of Proteins Is Required for Their Recognition by Ubiquitin-Protein Ligase", J. Biol. Chem., Vol. 265, No. 26, pp 15511-17, September 1990.

19.

Gale, E. AM., "Oral tolerance and autoimmune diabetes—will hope triumph over experience?", The Lancet, Vol. 356, August 12, 2000.

20.

Genain, C. P., et al., "Late Complications Of Immune Deviation Therapy in a Nonhuman Primate", Science, Vol. 274, December 20, 1996

21.

Gold, D. P., et al., "T-Cell Receptor Peptides as Immunotherapy for Autoimmune Disease", Critical Reviews™ In Immunology, Vol. 17, pp 507-510, 1997.

22.

Goodkin, D. E., et al., "A phase I trial of solubilized DR2:MBP⁸⁴⁻¹⁰² (AG284) in multiple sclerosis", Neurology, Vol. 54, pp 1414-1420, 2000.

23.

Haselden, B. M., et al., "Immunoglobulin E-Independent Major Histocompatibility Complex-Restricted T Cell Peptide Epitope-induced Late Asthmatic Reactions", J. Exp. Med., Vol. 189, No. 12, pp 1885-1894, June 21, 1999.

24.

Helm, B. A., et al., "Identification of the High Affinity Receptor Binding Region in Human Immunoglobulin E", The Journal of Biological Chemistry, Vol. 271, No. 13, Issue of March 29, pp. 7494-7500, 1996.

25.

Kappos, L., et al., "Induction of a non-encephalitogenic type 2 T helper-cell autoimmune response in multiple sclerosis after administration of an altered peptide ligand in a placebo-controlled, randomized phase II trial", Nature Medicine, Vol. 6, No. 10, pp 1176-1182, October 2000.

26.

Kepley, C. L., et al., "Negative regulation of FcεRI signaling by FcγRIIb costimulation in human blood basophils", Journal of Allergy and Clinical Immunology, Volume 106, Number 2, August 2000.

27.

Kinet, J-P, "THE HIGH-AFFINITY IGE RECEPTOR (FcεRI): From Physiology to Pathology", Annu. Rev. Immunol., Vol. 17, pp 931-72, 1999.

28.

Kisselev, A. F., "Proteasome Active Sites Allosterically Regulate Each Other, Suggesting A Cylindrical Bite-Chew Mechanism For Protein Breakdown", Molecular Cell, Vol. 4, pp 395-402, September, 1999.

29.

Luckey, C. J., et al., "Differences in the Expression of Human Class I MHC Alleles and Their Associated Peptides in the Presence of Proteasome Inhibitors", The Journal of Immunology, Vol. 167, pp 1212-1221, 2001.

30.

Lyczak, J. B., et al., "Expression Of Novel Secreted Isoforms of Human Immunoglobulin E Proteins", The Journal of Biological Chemistry, Vol. 271, No. 7, Issue of February 16, pp. 3428-3436, 1996.

31.

Marks, M. S. et al., "Protein Targeting by Tyrosine- and Di-leucine-based Signals: Evidence for Distinct Saturable Components", The Journal of Cell Biology, Vol. 135, No. 2, pp 341-354, October 1996.

32.

McFarland, H. F., "Complexities in the Treatment of Autoimmune Disease", Science, Vol. 274, December 20, 1996.

33.

Mikayama, T., et al., "Molecular cloning and functional expression of cDNA encoding glycosylation-inhibiting factor", Proc. Natl. Acad. Science, Vol. 90, pp 10056-10060, November 1993.

34.

Mocci, S., et al., "The role of autoantigens in autoimmune disease", Current Opinion in Immunology, Vol. 12, pp 725-730, 2000.


EXAMINER:

DATE CONSIDERED:

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.


*If an asterisk is placed beside the reference number, a copy is not provided because the reference was previously cited by or submitted to the PTO in a prior application that is identical in the statement and relied upon for an earlier filing date under 35 U.S.C. §120. 37 C.F.R. §1.98 (d).

SV 2112940 v1




Form PTO-1449		Attorney's Docket No. 39754-0672A	Application Serial No. 09/847,208
INFORMATION DISCLOSURE STATEMENT		Applicant(s) ANDREW SAXON et al.	
(use several sheets if necessary)		Filing Date: May 1, 2001	Group Art Unit: 1644
35.	Moreland, L. W., et al., "V β 17 T Cell Receptor Peptide Vaccination In Rheumatoid Arthritis: Results Of Phase I Dose Escalation Study", The Journal of Rheumatology, Vol. 23, No. 8, pp 1353-62, 1966.		
36.	Moreland, L. W., et al., "T Cell Receptor Peptide Vaccination In Rheumatoid Arthritis - A Placebo-Controlled Trial Using A Combination of V β 3, V β 14, and V β 17 Peptides", Arthritis & Rheumatism, Vol. 41, No. 11, pp. 1919-1929, November 1998.		
37.	Naquet, P., et al., "T Cell Autoreactivity To Insulin In Diabetic And Related Non-Diabetic Individuals", The Journal of Immunology, Vol. 140, No. 8, pp 2569-2578, April 15, 1988.		
38.	Nepom, G. T., et al., "Identification and modulation of a naturally processed T cell epitope from the diabetes-associated autoantigen human glutamic acid decarboxylase 65 (hGAD65)", PNAS, Vol. 98, No. 4, pp 1763-1768, February 13, 2001.		
39.	Nepom, G. T., "Glutamic acid decarboxylase and other autoantigens in IDDM", Current Opinion in Immunology, Vol. 7, pp 825-830, 1995.		
40.	Ota, K., et al., "T-cell recognition of an immunodominant myelin basic protein epitope in multiple sclerosis", Nature, Vol. 346, pp 183-187, July 12, 1990.		
41.	Pamer, E., et al., "Mechanisms of MHC Class I—Restricted Antigen Processing", Annu. Rev. Immunol., Vol. 16, pp 323-358, 1998.		
42.	Pozzilli, P., et al., "No effect of oral insulin on residual beta-cell function in recent-onset Type I diabetes (the IMDIAB VII)", Diabetologia, Vol. 43, pp 1000-1004, 2000.		
43.	Rock, K. L., et al., "Degradation of Cell Proteins and the Generation of MHC Class I-Presented Peptides", Annu. Rev. Immunol., Vol. 17, pp 739-79, 1999.		
44.	Sharma, S. D., et al., "Antigen-specific therapy of experimental allergic encephalomyelitis by soluble class II major histocompatibility complex—peptide complexes", Proc. Natl. Acad. Sci. USA, Vol. 88, pp 11465-11469, December 1991.		
45.	Slidregt, L., et al., "Design and Synthesis of a Multivalent Homing Device for Targeting to Murine CD22", Bioorganic & Medicinal Chemistry, Vol. 9, pp 85-97, 2001.		
46.	Spack, E. G., et al., "Induction of Tolerance in Experimental Autoimmune Myasthenia Gravis with Solubilized MHC Class II: Acetylcholine Receptor Peptide Complexes", Journal of Autoimmunity, Vol. 8, pp 787-807, 1995.		
47.	Stryer, L. et al, Biochemistry, Third Edition, W. H. Freeman Company, New York, New York, pp 31-33, 1998.		
48.	Steinman, L. et al., "Antigen Specific Immunotherapy Of Multiple Sclerosis", Journal of Clinical Immunology, Vol. 21, No. 2, pp 93-98, 2001.		
49.	TePas, E. C., et al, "Immunotherapy of asthma and allergic diseases", Current Opinion in Pediatrics, Vol. 12, pp 574-578, 2000.		
50.	Tunon, J. M. et al., "Immunoglobines E et cellules de l'inflammation", Rev. Mal. Resp., Vol. 13, pp 27-36, 1996:		

EXAMINER:	DATE CONSIDERED:
EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.	
*If an asterisk is placed beside the reference number, a copy is not provided because the reference was previously cited by or submitted to the PTO in a prior application that is identical in the statement and relied upon for an earlier filing date under 35 U.S.C. §120. 37 C.F.R. §1.98 (d).	
SV 2112940 v1	



Form PTO-1449		Attorney's Docket No. 39754-0672A	Application Serial No. 09/847,208
INFORMATION DISCLOSURE STATEMENT		Applicant(s) ANDREW SAXON et al.	
(use several sheets if necessary)		Filing Date: May 1, 2001	Group Art Unit: 1644
Pnk	51.	van Rossenberg, S. M. W., et al, "A Structure-Function Study of Ligand Recognition by CD22 β ", Journal of Biological Chemistry, Vol. 276, No. 16, Issue of April 20, pp 12967-12973, 2001.	
7	52.	Varshavsky, A., "The N-End Rule", Vol. 69, pp 725-735, May 29, 1992.	
	53.	Villadangos, J. A., "Proteases Involved in MHC class II antigen presentation", Immunological Reviews, Vol. 172, pp 109-120, 1999.	
	54.	Villadangos, Jose A., "Proteolysis in MHC Class II Antigen Presentation: Who's in Charge?", Immunity, Vol. 12, pp 233-239, March 2000.	
	55.	Warren, K.G., et al, "Fine specificity of the antibody response to myelin basic protein in the central nervous system in multiple sclerosis: the minimal B-cell epitope and a model of its features", Proc. Natl. Acad. Sci. USA, Vol. 92, pp 11061-11065, November 1995.	
	56.	Warren, K. G., "Increased synthetic peptide specificity of tissue-CSF bound anti-MBP in multiple sclerosis", Journal of Neuroimmunology, Vol. 43, pp 87-96, 1993.	
	57.	Warren, K. G., "Synthetic peptide specificity of anti-myelin basic protein from multiple sclerosis cerebrospinal fluid", Journal of Neuroimmunology, Vol. 39, pp 81-90, 1992.	
	58.	Warren, K.G., et al, "Tolerance Induction to myelin basic protein by intravenous synthetic peptides containing epitope P ₁₅ VVHFFKNIVTP ₉₆ in chronic progressive multiple sclerosis", Journal of Neurological Sciences, Vol. 152, pp 31-38, 1997.	
	59.	Watts, C., "Antigen processing in the endocytic compartment", Current Opinion in Immunology", Vol. 13, pp 26-31, 2001.	
	60.	Watts, C., "Capture and Processing of Exogenous Antigens for Presentation on MHC Molecules", Annu. Rev. Immunol., Vol. 15, pp 821-850, 1997.	
	61.	Weiner, H. L., et al., "Double-Blind Pilot Trial of Oral Tolerization with Myelin Antigens in Multiple Sclerosis", Science, Vol. 259, pp 1321-1324, February 26, 1993.	
	62.	Wucherpfennig, K. W., et al, "Recognition of the Immunodominant Myelin Basic Protein Peptide by Autoantibodies and HLA-DR2-restricted T Cell Clones from Multiple Sclerosis Patients", J. Clin. Invest., Vol. 100, No. 5, pp 1114-1122, September 1997.	
	63.	Yodoi, J., et al, "Low affinity IgE receptors: regulation and functional roles in cell activation", Ige, Mast Cells and the Allergic Response, Wiley Chichester (Ciba Foundation Symposium 147) pp 133-153, 1989.	
✓	64.	Yoon, J-W., et al, "Control of Autoimmune Diabetes in NOD Mice by GAD Expression or Suppression in β Cells", Science, Vol. 284, pp 1183-1187, May 14, 1999.	

EXAMINER:	DATE CONSIDERED:
	11/29/05
EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.	
*If an asterisk is placed beside the reference number, a copy is not provided because the reference was previously cited by or submitted to the PTO in a prior application that is identical in the statement and relied upon for an earlier filing date under 35 U.S.C. §120. 37 C.F.R. §1.98 (d).	
SV 2112940 v1	



Form PTO-1449				Attorney's Docket No. 39754-0672A		Application Serial No. 09/847,208	
INFORMATION DISCLOSURE STATEMENT				Applicant(s) ANDREW SAXON et al.			
(use several sheets if necessary)				Filing Date: May 1, 2001		Group Art Unit: 1644	
U.S. PATENT DOCUMENTS							
Examiner Initials	Ref. No.	Date	Document No.	Name	Class	Subclass	Filing Date (if appropriate)
FOREIGN PATENT DOCUMENTS							
Examiner Initials	Ref. No.	Date	Document No.	Name	Class	Subclass	Translation YES NO
PNT	4.	12-19-1986	WO 96/40789	Duplicate	C07K	16/46	
OTHER DOCUMENTS (including author, title, date, pertinent pages, etc.)							
Examiner Initials	Ref. No.	Title					
PNT	1.	Harrison, L.C. and Hafler, D.A., "Antigen-Specific Therapy for Autoimmune Disease," Current Opinion in Immunology, Vol. 12, pp 704-711, 2000.					
	2.	Kaplan, A.P., "Urticaria and Angioedema," Inflammation: Basic Principles and Clinical Correlates, (Gallin and Snyderman eds.), 3rd Edition, Lippincott & Wilkins, Philadelphia, 1999, pp. 915-928.					
	3.	McDevitt, H., "Specific Antigen Vaccination to Treat Autoimmune Disease," PNAS, Vol. 101:(2), pp 14627-14630 (October 5, 2004).					
	4.	Pivnyuk, V.I. et al., "Human Low-Affinity IgE Receptor: cDNA from Cell Line 1B and Its Expression in Peripheral Blood Cells," Molecular Biology, Vol. 28:(4), Part 2, pp 549-552 (1994).					
	5.	Tisch, R. et al., "Antigen-Specific Mediated Suppression of β Cell Autoimmunity by Plasmid DNA Vaccination," The Journal of Immunology, Vol. 166, pp 2122-2132 (2001).					
	6.	Warren, K.G., et al, "Fine Specificity of the Antibody Response to Myelin Basic Protein in the Central Nervous System in Multiple Sclerosis: The Minimal B-Cell Epitope and a Model of its Features", Proc. Natl. Acad. Sci. USA, Vol. 92, pp 11061-11065, (November 1995).					
	7.	Warren, K. G., "Increased Synthetic Peptide Specificity of Tissue-CSF Bound Anti-MBP in Multiple Sclerosis", Journal of Neuroimmunology, Vol. 43, pp 87-96, (1993).					
	8.	Warren, K. G., "Synthetic Peptide Specificity of Anti-Myelin Basic Protein from Multiple Sclerosis Cerebrospinal Fluid", Journal of Neuroimmunology, Vol. 39, pp 81-90, (1992).					
	9.	Warren, K.G., et al, "Tolerance Induction to Myelin Basic Protein by Intravenous Synthetic Peptides Containing Epitope P ₂₅ VVHFFKNIVTP ₉₆ in Chronic Progressive Multiple Sclerosis", Journal of Neurological Sciences, Vol. 152, pp 31-38, (1997).					
✓	10.	Weiner, H. L., "Double-Blind Pilot Trial of Oral Tolerization with Myelin Antigens in Multiple Sclerosis", Science, Vol. 259, pp 1321-1324, (February 26, 1993).					

EXAMINER:	DATE CONSIDERED:
<i>[Signature]</i>	11/29/05
EXAMINER: Initials if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.	
*If an asterisk is placed beside the reference number, a copy is not provided because the reference was previously cited by or submitted to the PTO in a prior application that is identical in the statement and relied upon for an earlier filing date under 35 U.S.C. §120. 37 C.F.R. §1.98 (d).	
SV 2154502 v1	